Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130845 · ClinicalTrials.gov registry record · Phase 3
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
A Phase 3 study of Diabetic Retinopathy, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
- 1
- Study location
NCT00130845 is a Phase 3 study of Diabetic Retinopathy that has completed, run by Novartis. The registered enrollment target is 312 participants, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00130845, a Phase 3 study of Diabetic Retinopathy, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
- 1
- Study location
Study Summary
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Octreotide Acetate in Microspheres
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2000-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130845
The ClinicalTrials.gov registry entry for NCT00130845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (81% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00130845 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00130845 about?
NCT00130845 is a clinical study titled "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy". The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and p...
What is the current status of trial NCT00130845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2000-02. Estimated completion is 2005-12.
What conditions does trial NCT00130845 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT00130845?
The interventions under investigation include: Placebo (DRUG), Octreotide Acetate in Microspheres (DRUG).
Who is sponsoring clinical trial NCT00130845?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130845 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
COMPLETED · Phase 3
-
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
COMPLETED · Phase 3
-
Anti-VEGF Treatment for Prevention of PDR/DME
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.